With markets on edge over aggressive AI spending by Alphabet and Tesla, rising oil prices, and higher bond yields, many investors are looking past high growth stories and toward steadier dividend payers. Large cap defensive dividend stocks can sometimes offer a different way to think about risk by focusing on cash flows and business resilience when sentiment swings. This article looks at 3 stocks from a Large Cap Defensive Dividend Stocks screener that appear closely tied to the latest macro headlines and explains how the same news that is pressuring broader indices could matter for each one.

Elevance Health (ELV)

Overview: Elevance Health is a large US health benefits company that offers medical, pharmacy, and specialty insurance plans across commercial, Medicare, Medicaid, and federal programs, supported by its Carelon pharmacy and services businesses. It provides everything from traditional health coverage and managed care administration to behavioral health, virtual care, and data and analytics services under brands such as Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon.

Operations: Elevance Health generates most of its revenue in the United States, with around US$169.3b from Health Benefits, US$44.5b from Carelon Rx, and US$29.7b from Carelon Services, partly offset by eliminations within the group.

Market Cap: US$82.3b

Elevance Health may appeal to investors who prioritize dividends and cash flows when high growth tech stocks are under pressure. The core health benefits business, together with Carelon’s pharmacy and services arms, spreads revenue across commercial, Medicare, and Medicaid members. Technology and AI investments are intended to help manage medical and administrative costs. At the same time, there are questions around Medicaid profitability, medical cost trends, and execution on acquisitions that have already weighed on recent earnings and margins. Insider share purchases by the CEO and Chairman indicate internal confidence. For investors, the balance between valuation, dividend income, and policy risk is a key aspect of the investment case.

Elevance Health’s AI and services push could be masking a very different earnings and dividend story than headline worries around Medicaid and medical costs suggest. Get the full context in the analysis report for Elevance Health

Bristol-Myers Squibb (BMY)

Overview: Bristol-Myers Squibb is a global biopharmaceutical company that develops and sells prescription medicines across cancer, blood disorders, immune and cardiovascular diseases, and neuroscience, with a portfolio that includes widely used therapies such as Opdivo, Eliquis, Revlimid, Orencia, Yervoy, and newer launches like Camzyos, Sotyktu, and Cobenfy.

Operations: Bristol-Myers Squibb generates essentially all of its US$48.5b in revenue from pharmaceuticals, with about US$33.2b from the United States and US$14.2b from international markets.

Market Cap: US$124.1b

Bristol-Myers Squibb may appeal to investors looking for a defensive dividend stock that is less tied to AI spending cycles and energy price swings, supported by a 4.1% dividend yield and a broad portfolio in areas such as oncology and cardiovascular disease. The company is working to address looming patent expiries on key drugs such as Eliquis and Opdivo through an expanding late stage pipeline, new approvals for products like Sotyktu and Opdivo combinations, and collaborations that use AI and external partners to support clinical development. At the same time, high debt, forecast revenue declines and a large recent one off loss highlight execution risk, particularly if new launches or acquisitions do not meet expectations.

Bristol-Myers Squibb’s high yield and late stage pipeline could be masking a very different risk reward profile than its recent headlines suggest, and the full story only comes into focus in the 3 key rewards and 3 important warning signs (1 is major!)

Johnson & Johnson (JNJ)

Overview: Johnson & Johnson is a global healthcare company that develops prescription medicines across areas such as oncology and immunology, and sells medical devices and technologies used in surgery, orthopedics, cardiovascular care and eye health, including ACUVUE contact lenses and TECNIS intraocular lenses.

Operations: Johnson & Johnson generates about US$63.1b from its Innovative Medicine segment and US$34.8b from MedTech products, with sales spread across the United States, Europe and other international markets.

Market Cap: US$615.4b

Johnson & Johnson appears in this Large Cap Defensive Dividend Stocks screener as a healthcare company combining a history of dividend growth with exposure to areas like oncology, immunology and robotic surgery. The company is investing over US$55b into US manufacturing, R&D and technology, including its OTTAVA robotic surgical platform. MedTech acquisitions and pipeline drugs such as Tremfya and Darzalex have featured in recent earnings updates. At the same time, legal overhang from talc litigation, loss of exclusivity on certain drugs and a relatively high P/E and debt load may limit flexibility. For income focused investors watching AI heavy stocks sell off, the Johnson & Johnson story can be more nuanced than a simple defensive label suggests.

Johnson & Johnson’s dividend record and US$55b reinvestment push hint that the current story may be only half written, and the real twist sits in the analyst forecasts for Johnson & Johnson

The three dividend stocks covered here are only a starting point, as the full Large Cap Defensive Dividend Stocks screener on Simply Wall St highlights 21 more companies with equally compelling income and resilience stories inside the Large Cap Defensive Dividend Stocks screener. Use the Simply Wall St platform to identify and analyze the specific catalysts, balance sheet strength, dividend track records and business narratives that fit your highest conviction ideas.

Take Control of Your Investment Journey

If Bristol-Myers Squibb or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Beyond Dividends?

Some of the most interesting ideas move first, then headlines catch up. Scan fresh stock sets built for breakout potential before momentum is fully caught, and consider acting before they become widely followed.

• Spot early strength in smaller companies before momentum screens get crowded by checking out the 79 resilient stocks with low risk scores that focuses on sturdier fundamentals with contained downside.
• Track powerful income streams while yields are still flying under the radar with the curated 7 dividend fortresses that prioritizes sustainability alongside payout size.
• Follow structural tailwinds in critical materials before the crowd notices supply constraints by scanning the focused 8 top copper producer stocks built around producers influencing long term demand.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.